ECSP045369A - Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica

Info

Publication number
ECSP045369A
ECSP045369A EC2004005369A ECSP045369A ECSP045369A EC SP045369 A ECSP045369 A EC SP045369A EC 2004005369 A EC2004005369 A EC 2004005369A EC SP045369 A ECSP045369 A EC SP045369A EC SP045369 A ECSP045369 A EC SP045369A
Authority
EC
Ecuador
Prior art keywords
group
hydrogen atom
general formula
benzamida
metil
Prior art date
Application number
EC2004005369A
Other languages
English (en)
Inventor
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Pascale Magat
Benoit Marabout
Florence Medaisko
Pierre Pierre Roger
Mireille Sevrin
Corinne Veronique
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP045369A publication Critical patent/ECSP045369A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos de fórmula general (I): en la cual:A representa o bien un grupo de fórmula general N-R1 en la cual R1 representa un átomo de hidrógeno, un grupo alquilo, un grupo cicloalquilo, un grupo fenilalquilo, un grupo alquenilo o un grupo alquinilo,o bien un grupo de fórmula N+ (O-)R1 en la cual R1 es tal como se ha definido anteriormente, o también un grupo de fórmula N+(R=)R1 en la cual R= representa un grupo alquilo y R1 es tal como se ha definido anteriormente, X representa un átomo de hidrógeno o uno o varios substituyentes elegidos entre los átomos de halógenos y los grupos trifluorometilo, alquilo y alcoxi, R2 representa un átomo de hidrógeno, o uno o varios substituyentes elegidos entre los átomos de halógenos y los grupos trifluorometilo, alquilos, alcoxi, amino de fórmula general NR3R4 en la cual R3 y R4 representan cada uno, un átomo de hidrógeno o un grupo alquilo, o forman con el átomo de nitrógeno que los lleva, un ciclo pirrolidino, piperidino o morfolino, o bien un grupo fenilo eventualmente substituido.Aplicación en terapéutica.
EC2004005369A 2002-04-19 2004-10-18 Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica ECSP045369A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204916A FR2838739B1 (fr) 2002-04-19 2002-04-19 Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ECSP045369A true ECSP045369A (es) 2005-03-10

Family

ID=28686193

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005369A ECSP045369A (es) 2002-04-19 2004-10-18 Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica

Country Status (35)

Country Link
US (2) US7326722B2 (es)
EP (1) EP1499589B1 (es)
JP (1) JP4597532B2 (es)
KR (2) KR20040103973A (es)
CN (1) CN100482646C (es)
AR (1) AR039413A1 (es)
AT (1) ATE361279T1 (es)
AU (1) AU2003262420B2 (es)
BR (1) BR0309397A (es)
CA (1) CA2481461C (es)
CO (1) CO5631432A2 (es)
CY (1) CY1108025T1 (es)
DE (1) DE60313602T2 (es)
DK (1) DK1499589T3 (es)
EA (1) EA007225B1 (es)
EC (1) ECSP045369A (es)
ES (1) ES2286444T3 (es)
FR (1) FR2838739B1 (es)
HR (1) HRP20040977B1 (es)
IL (2) IL164400A0 (es)
IS (1) IS2540B (es)
MA (1) MA27192A1 (es)
ME (1) MEP25608A (es)
MX (1) MXPA04010326A (es)
NO (1) NO329065B1 (es)
NZ (1) NZ536015A (es)
PL (1) PL373195A1 (es)
PT (1) PT1499589E (es)
RS (1) RS51888B (es)
SI (1) SI1499589T1 (es)
TN (1) TNSN04208A1 (es)
TW (1) TWI306402B (es)
UA (1) UA78025C2 (es)
WO (1) WO2003089411A1 (es)
ZA (1) ZA200408154B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
WO2005044810A1 (en) * 2003-10-30 2005-05-19 Janssen Pharmaceutica, N.V. Glyt2 modulators
CA2609972C (en) * 2004-03-22 2013-05-14 Apkarian Technologies Llc Method and compositions for treatment of chronic neuropathic pain
GEP20105053B (en) * 2005-04-08 2010-07-26 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
JP2009179562A (ja) * 2006-08-11 2009-08-13 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
MX2009014235A (es) * 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
EP2527328A1 (en) * 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Trpm8拮抗剤及び治療におけるそれらの使用
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
FR2983197B1 (fr) * 2011-11-29 2014-07-25 Assist Publ Hopitaux De Paris Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602935PA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
FR3045044B1 (fr) * 2015-12-11 2019-04-19 Liphatech Composition et appat rodonticide comprenant du flocoumafene, procede de lutte contre des rongeurs cibles nuisibles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US5524569A (en) * 1995-03-20 1996-06-11 Rich; William A. Anchor cover
EP1058684A1 (en) * 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
EP1296950A2 (en) * 2000-04-20 2003-04-02 NPS Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors

Also Published As

Publication number Publication date
US7326722B2 (en) 2008-02-05
FR2838739A1 (fr) 2003-10-24
NO329065B1 (no) 2010-08-09
ZA200408154B (en) 2005-10-10
IS7479A (is) 2004-09-30
EP1499589A1 (fr) 2005-01-26
CN100482646C (zh) 2009-04-29
US20050159450A1 (en) 2005-07-21
CA2481461C (en) 2010-01-12
CY1108025T1 (el) 2013-09-04
DK1499589T3 (da) 2007-09-10
TW200306830A (en) 2003-12-01
WO2003089411A1 (fr) 2003-10-30
JP2005527593A (ja) 2005-09-15
EA200401172A1 (ru) 2005-04-28
FR2838739B1 (fr) 2004-05-28
TWI306402B (en) 2009-02-21
IS2540B (is) 2009-09-15
MA27192A1 (fr) 2005-01-03
KR101019313B1 (ko) 2011-03-07
CO5631432A2 (es) 2006-04-28
CN1662497A (zh) 2005-08-31
RS51888B (sr) 2012-02-29
IL164400A (en) 2010-11-30
HRP20040977B1 (hr) 2008-04-30
IL164400A0 (en) 2005-12-18
SI1499589T1 (sl) 2007-10-31
DE60313602T2 (de) 2008-01-10
NZ536015A (en) 2006-11-30
KR20080075236A (ko) 2008-08-14
TNSN04208A1 (fr) 2007-03-12
RS91404A (sr) 2007-02-05
EA007225B1 (ru) 2006-08-25
MXPA04010326A (es) 2005-07-05
AU2003262420A1 (en) 2003-11-03
CA2481461A1 (en) 2003-10-30
HRP20040977A2 (en) 2004-12-31
US20070197601A1 (en) 2007-08-23
PT1499589E (pt) 2007-08-10
DE60313602D1 (de) 2007-06-14
KR20040103973A (ko) 2004-12-09
PL373195A1 (en) 2005-08-22
ES2286444T3 (es) 2007-12-01
MEP25608A (en) 2010-06-10
UA78025C2 (en) 2007-02-15
JP4597532B2 (ja) 2010-12-15
BR0309397A (pt) 2005-03-01
NO20044388L (no) 2005-01-19
AR039413A1 (es) 2005-02-16
EP1499589B1 (fr) 2007-05-02
ATE361279T1 (de) 2007-05-15
AU2003262420B2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
ECSP045369A (es) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE338461T1 (de) Pyrazolpyrimidinfungizide
AR050267A1 (es) Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0506817A (pt) inibidores seletivos de quinase
PE20030890A1 (es) Cumarinas utiles como biomarcadores
AR055878A1 (es) Derivados de ciclopropanocarboxamida
DK1414302T3 (da) 7-aminotriazolopyrimidiner til bekæmpelse af skadelige svampe
PY08034070A (es) Derivados de 1, 2, 4, 5-tetrahidro -3-H- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
MEP12708A (en) Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
FR2842804B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CO5031250A1 (es) Compuesto farmaceutico
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DE69507293D1 (de) Benzamid-derivate als vasopressin-antagonisten
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
CO5580748A2 (es) 4-fenil-tetrahidro-isoquinolinas sustituidas, procedimiento para su preparacion, su uso como medicamento, y medicamento que las contienen
AR040570A1 (es) Deriados de acilaminotiazol, su preparacion y su aplicacion en terapeutica
CR7249A (es) Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo
ES2177275T3 (es) Derivados de oxadiazolina y su uso como insecticidas.
PE20080335A1 (es) Moleculas duales que contienen un derivado peroxidico, su sintesis y sus aplicaciones terapeuticas